← Back to Search

Enzyme Inhibitor

Rho-Kinase Inhibitor for Glaucoma (ROCK - CACG Trial)

Phase 2

Waitlist Available

Research Sponsored by New York Glaucoma Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No previous intraocular surgery except clear cornea phacoemulsification

Patients with CACG with ≥180⁰ PAS

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

ROCK - CACG Trial Summary

This trial is testing a Rho kinase inhibitor as a potential treatment for chronic angle-closure glaucoma. The objectives are to evaluate the efficacy of the drug in reducing intraocular pressure, both in the short and long term, and to determine if the drug can be used to reduce or eliminate the structural blockage that leads to the development of elevated intraocular pressure in chronic angle-closure glaucoma.

Who is the study for?

This trial is for people aged 50-85 with chronic angle-closure glaucoma, vision of at least 20/50, and eye pressure ≥22 mmHg. They must be able to attend a 6-month study and have not had certain eye surgeries or systemic diseases that could affect the study.Check my eligibility

What is being tested?

The trial tests Rho-Kinase Inhibitor (AR-12286) ophthalmic solutions at two different strengths (0.5% and 0.7%) to see if they lower eye pressure in patients with chronic angle-closure glaucoma over six months.See study design

What are the potential side effects?

Possible side effects may include mild discomfort in the eyes, potential allergic reactions to ingredients like benzalkonium chloride, or other unspecified effects related to lowering intraocular pressure.

ROCK - CACG Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have only had cataract surgery on my eye.

Select...

I have advanced angle-closure glaucoma.

ROCK - CACG Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Long Lasting effect of study drug to reduce IOP

Secondary outcome measures

ROCK - CACG Trial Design

2Treatment groups

Experimental Treatment

Group I: 0.7% Rho-Kinase InhibitorExperimental Treatment1 Intervention

AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.

Group II: 0.5% Rho-Kinase InhibitorExperimental Treatment1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

New York Glaucoma Research InstituteLead Sponsor

2 Previous Clinical Trials

20 Total Patients Enrolled

Media Library

AR-12286 Ophthalmic Solution (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02152774 — Phase 2

Angle-Closure Glaucoma Research Study Groups: 0.7% Rho-Kinase Inhibitor, 0.5% Rho-Kinase Inhibitor

Angle-Closure Glaucoma Clinical Trial 2023: AR-12286 Ophthalmic Solution Highlights & Side Effects. Trial Name: NCT02152774 — Phase 2

AR-12286 Ophthalmic Solution (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02152774 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can I be considered for this research study?

"This research project is searching for 10 glaucoma patients aged between 50 and 85 years old. Individuals hoping to be considered must satisfy the following prerequisites: possess a minimum of 180° peripheral anterior synechiae, have provided written consent prior to participating in any investigations, display no more than 3 diopters cylinder equivalent on their study eye as determined by an ophthalmologist , exhibit intraocular pressure (IOP) exceeding 22mmHg over two separate measurements separated by 2 hours, have never undergone any kind of surgical procedures within the eye save clear cornea phacoemulsification, demonstrate 20/50 corrected visual"

Answered by AI

Is this experiment currently accepting research volunteers?

"As advertised on clinicaltrials.gov, this specific trial is not currently open to enrollment. This investigation was initially posted on May 1st 2014 and last updated April 23rd 2015. Despite the current lack of opportunity for applicants, 207 other trials are actively searching for participants at present time."

Answered by AI

Did the US Food and Drug Administration officially authorize Rho-Kinase Inhibitor?

"As this is a phase 2 trial, with safety data but no efficacy evidence, Rho-Kinase Inhibitor was given an estimated score of 2 on the Power team's scale."

Answered by AI

Are individuals over the age of 40 eligible to enroll in this experiment?

"According to the inclusion requirements, this trial is only available for adults between 50 and 85 years old. However, there are 23 studies for minors and 192 trials for senior citizens who meet the criteria."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

Jessica Jasien 2014. "A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02152774.

All > Uti > Glaucoma